NEVVI Medicare utilization intelligence

← back

MEHDI, RAJAMD NPI 1366441743 Clinician

Medical Oncology · LAS VEGAS, NV

Specialty Medical Oncology — from billed Medicare claims
In practice about 29 years since medical school (class of 1997, self-reported to CMS)
Location LAS VEGAS, NV · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 41 codes billed · 111,792 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
AMERICAN ONCOLOGY PARTNERS PA
2020–2026
RAJA S. MEHDI MD PLLC
2019

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2023-01

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Unlock to see the figure.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
J0185 Injection, aprepitant, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9271 Injection, pembrolizumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
J1437 Injection, ferric derisomaltose, 10 mg
J9190 Injection, fluorouracil, 500 mg
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
J2405 Injection, ondansetron hydrochloride, per 1 mg
J0640 Injection, leucovorin calcium, per 50 mg
36415 Insertion of needle into vein for collection of blood sample
J3489 Injection, zoledronic acid, 1 mg
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
96375 Injection of additional new drug or substance into vein
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J2919 Injection, methylprednisolone sodium succinate, 5 mg
96372 Injection of drug or substance under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
96523 Irrigation of implanted venous access drug delivery device
96417 Administration of additional new drug or substance into vein, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J3490 Unclassified drugs
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96411 Administration of additional new drug or substance into vein using push technique
96416 Administration of prolonged chemotherapy into vein
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
99426 Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.